A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

ConclusionsBevacizumab is not cost-effective when combined with chemotherapy for patients with advanced nonsquamous NSCLC based on the Chinese health care system, resulting in a less demand in the Chinese market.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research